Skov Jane, Sidelmann Johannes J, Bladbjerg Else-Marie, Jespersen Jørgen, Gram Jørgen
Unit for Thrombosis Research, Institute of Public Health, University of Southern Denmark, Esbjerg, Denmark; Department of Clinical Biochemistry, Hospital of South West Denmark, Esbjerg, Denmark.
Unit for Thrombosis Research, Institute of Public Health, University of Southern Denmark, Esbjerg, Denmark; Department of Clinical Biochemistry, Hospital of South West Denmark, Esbjerg, Denmark.
Thromb Res. 2014 Sep;134(3):717-22. doi: 10.1016/j.thromres.2014.06.031. Epub 2014 Jul 5.
Atrial fibrillation increases the risk of ischemic stroke, but the risk depends on other factors as well. Present risk stratification schemes use age and co-morbidities, but not biochemical markers. We investigated the hypothesis that the formation, structure and lysability of fibrin clots are potential determinants of stroke risk in patients with atrial fibrillation.
A total of 179 patients with atrial fibrillation in stable anticoagulant treatment were included. Thirty-two had a previous ischemic stroke. We measured thrombin generation, plasma concentrations of fibrinogen and C-reactive protein and analysed fibrin structure and lysability by turbidity. Fibrinolytic capacity was measured using the euglobulin fraction of plasma expressed in terms of t-PA equivalents (IU/ml).
The patients with previous stroke had a slightly higher burden of co-morbidities compared with the remaining patients as indicated by the CHA2DS2-VASc score, but no significant differences were found regarding age, fibrinogen concentration, C-reactive protein, thrombin generation or fibrinolytic capacity. Furthermore, the patients with previous stroke had a higher mass/length ratio of fibrin fibers (5.5 vs. 5.1 x10(12) Da/cm, p=0.044) and an increased lysability (79.3 vs. 55.3%, p<0.01).
The higher lysability of fibrin clots in atrial fibrillation patients with previous stroke is most likely a result of a difference in fibrin fiber properties. An increased lysability may increase the risk of embolization of clots formed in the atria, and therefore fibrin clot structure seems to be a determinant of stroke risk in atrial fibrillation.
心房颤动会增加缺血性中风的风险,但该风险还取决于其他因素。目前的风险分层方案使用年龄和合并症,但未使用生化标志物。我们研究了以下假设:纤维蛋白凝块的形成、结构和可溶解性是心房颤动患者中风风险的潜在决定因素。
共纳入179例接受稳定抗凝治疗的心房颤动患者。其中32例曾有缺血性中风病史。我们测量了凝血酶生成、纤维蛋白原和C反应蛋白的血浆浓度,并通过比浊法分析了纤维蛋白结构和可溶解性。使用以组织型纤溶酶原激活剂(t-PA)当量(IU/ml)表示的血浆优球蛋白组分来测量纤溶能力。
根据CHA2DS2-VASc评分,曾有中风病史的患者与其余患者相比,合并症负担略高,但在年龄、纤维蛋白原浓度、C反应蛋白、凝血酶生成或纤溶能力方面未发现显著差异。此外,曾有中风病史的患者纤维蛋白纤维的质量/长度比更高(5.5对5.1×10¹²Da/cm,p = 0.044),可溶解性增加(79.3%对55.3%,p<0.01)。
曾有中风病史的心房颤动患者纤维蛋白凝块的较高可溶解性很可能是纤维蛋白纤维特性差异的结果。可溶解性增加可能会增加心房形成的凝块发生栓塞的风险,因此纤维蛋白凝块结构似乎是心房颤动中风风险的一个决定因素。